Core Viewpoint - The stock of Zhongguancun (000931) has shown a slight increase, with a closing price of 4.9 yuan on December 18, 2025, reflecting a 1.45% rise, amidst mixed capital flows from different investor types [1][2]. Group 1: Stock Performance - On December 18, 2025, Zhongguancun's stock closed at 4.9 yuan, up by 1.45%, with a trading volume of 68,300 hands and a total transaction amount of 33.3955 million yuan [1]. - The capital flow data indicates a net inflow of 2.2932 million yuan from institutional investors, accounting for 6.87% of the total transaction amount, while retail investors saw a net inflow of 3.304 million yuan, representing 9.89% [1][2]. Group 2: Recent Capital Flows - Over the past five days, the stock has experienced varying capital flows, with the highest net inflow from institutional investors recorded on December 12, 2025, at 8.5572 million yuan, while the largest net outflow from retail investors occurred on the same day at 10.8397 million yuan [2]. - The net capital flow data for December 17, 2025, showed a net inflow of 4.1618 million yuan from institutional investors, while retail investors had a net outflow of 1.7481 million yuan [2]. Group 3: Company Financials and Industry Position - Zhongguancun's total market capitalization is 3.69 billion yuan, significantly lower than the chemical pharmaceutical industry average of 14.017 billion yuan, ranking 117 out of 148 companies [3]. - The company reported a net profit of 49.4914 million yuan for the first three quarters of 2025, a decrease of 4.14% year-on-year, with a gross margin of 59.64%, which is higher than the industry average of 48.87% [3]. - The company's main business segments include biopharmaceuticals, health products, elderly care services, and commercial concrete, with a focus on the development and sales of various pharmaceutical forms and health-related services [3].

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. has received FDA approval for its injectable Bortezomib ANDA, marking a significant milestone in its international expansion and product portfolio enhancement [1] Group 1: Company Performance - As of December 18, 2025, *ST Shuangcheng (002693) closed at 6.58 yuan, down 0.3% from the previous trading day, with a total market capitalization of 2.729 billion yuan [1] - The stock opened at 6.59 yuan, reached a high of 6.79 yuan, and a low of 6.55 yuan, with a trading volume of 32.0879 million yuan and a turnover rate of 1.17% [1] Group 2: Regulatory Approvals - The injectable Bortezomib ANDA has been recognized by the FDA as being bioequivalent and therapeutically equivalent to the reference drug [1] - The product has also received approval from the National Medical Products Administration of China and has passed the consistency evaluation, along with obtaining listing permission from Australia's TGA [1] Group 3: Strategic Implications - The FDA approval signifies that the company's product meets international standards, which is expected to enhance its international influence and operational performance [1] - This development will enrich the company's international sales product line and advance its globalization strategy [1] - The announcement also notes that overseas sales may be affected by regulations, policies, market conditions, and exchange rate fluctuations [1]

毕得医药12月18日大宗交易平台共发生3笔成交，合计成交量16.74万股，成交金额1004.40万元。成交价 格均为60.00元，相对今日收盘价折价7.25%。从参与大宗交易营业部来看，机构专用席位共出现在1笔 成交的买方或卖方营业部中，合计成交金额为204.00万元，净买入204.00万元。 进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为6055.01万元。 两融数据显示，该股最新融资余额为2869.09万元，近5日减少268.76万元，降幅为8.57%。 据天眼查APP显示，上海毕得医药科技股份有限公司成立于2007年04月27日，注册资本9088.2948万人 民币。（数据宝） 12月18日毕得医药大宗交易一览 | 成交量 （万 | 成交金额 | 成交价 格 | 相对当日收盘 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 股） | （万元） | （元） | 折溢价（%） | | | | 10.00 | 600.00 | 60.00 | -7.25 | 广发证券股份有限公司总部 | 浙商证券股份有限公司上 | | | ...

证券日报网讯 12月18日晚间，海思科（002653）发布公告称，公司于2025年12月18日收到政府补助 12000万元。 ...

海思科公告，公司于2025年12月18日收到深圳证券交易所上市审核中心出具的《关于海思科医药集团股 份有限公司申请向特定对象发行股票的审核中心意见告知函》。深交所上市审核中心对公司提交的向特 定对象发行股票的申请文件进行了审核，认为公司符合发行条件、上市条件和信息披露要求。公司本次 向特定对象发行股票的事宜尚需获得中国证监会同意注册的批复后方可实施。 ...

毕得医药公告，公司股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、蒋亚妹于2025年9月18日至2025 年12月17日期间合计减持公司股份437,902股，占公司总股本的0.48%。其中，李怡静减持91,673股，减 持价格区间为75.00元/股至82.00元/股，减持总金额为7,245,513元；陈俊减持136,395股，减持价格区间 为70.56元/股至77.80元/股，减持总金额为9,931,500元；李黎减持10,000股，减持价格区间为66.65元/股 至82.20元/股，减持总金额为796,133元；杜鹃减持56,500股，减持价格区间为72.00元/股至76.00元/股， 减持总金额为3,800,000元；李爱飞减持63,255股，减持价格区间为78.50元/股至82.00元/股，减持总金额 为4,991,075元；耿勇减持32,119股，减持价格区间为65.20元/股至81.12元/股，减持总金额为2,404,480 元；蒋亚妹减持47,960股，减持价格区间为77.04元/股至79.03元/股，减持总金额为3,747,171元。 ...

第3笔成交价格为60.00元，成交3.34万股，成交金额200.40万元，溢价率为-7.25%，买方营业部为瑞银 证券有限责任公司上海花园石桥路证券营业部，卖方营业部为浙商证券股份有限公司上海长乐路证券营 业部。 进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为6055.01万元。该股近5个交易日 累计下跌3.45%，主力资金合计净流出501.35万元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月18日，毕得医药收跌1.57%，收盘价为64.69元，发生3笔大宗交易，合计成交量16.74万股，成交金 额1004.4万元。 第1笔成交价格为60.00元，成交10.00万股，成交金额600.00万元，溢价率为-7.25%，买方营业部为广发 证券股份有限公司总部，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。 第2笔成交价格为60.00元，成交3.40万股，成交金额204.00万元，溢价率为-7.25%，买方营业部为机构 专用，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。 ...

Core Viewpoint - The company emphasizes its clear medium to long-term development plan, focusing on sustainable development driven by green and intelligent chemical technology innovation [1] Group 1: Development Strategy - The company's key tasks include advancing digitalization and intelligence in management systems [1] - Strengthening compliance systems and scaling up production capacity is a priority [1] - The company aims to accelerate the layout of new molecular businesses such as TIDES and XDC [1] Group 2: Market Adaptation - The company is adapting to changes in the international biopharmaceutical investment environment, which has led to fluctuations in downstream demand [1] - Investment pace has been prudently planned and dynamically adjusted based on market demand, capacity layout, and usage efficiency to maximize shareholder interests [1] - The company will continue to monitor environmental changes and make reasonable arrangements for the use of raised funds [1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流出4.98亿元，游资资金净流入7193.04万元，散户资 金净流入4.26亿元。化学制药板块个股资金流向见下表： 证券之星消息，12月18日化学制药板块较上一交易日下跌0.04%，益方生物领跌。当日上证指数报收于 3876.37，上涨0.16%。深证成指报收于13053.98，下跌1.29%。化学制药板块个股涨跌见下表： ...

Core Viewpoint - The company announced that 17,840,700 restricted shares will be listed for trading on December 25, 2025, representing 9.44% of the total share capital [1] Group 1 - The company completed the registration of A-share issuance to specific targets on June 25, 2025, increasing the total share capital from 171,188,958 shares to 189,029,624 shares [1] - All shareholders of the restricted shares have committed to not transferring their shares within six months from the end of the issuance [1] - The sponsoring institution has no objections regarding the listing of the restricted shares [1]